物料
device (thermoplastic elastomer)
polyethylene device
polypropylene device
silicone device
质量水平
Agency
according to ISO 11137
meets EN 2.6.14
meets JP 4.01
meets USP 85
无菌性
sterile; γ-irradiated (at 25-40 kGy)
产品线
Mobius®
参数
-80-60 °C temp. range (-112-140 °F)
0.3 bar max. pressure (4.4 psi)
60 mL process volume
容量
100 mL
杂质
<0.25 EU/mL Aqueous extraction (LAL test)
应用
mAb
储存温度
2-30°C
正在寻找类似产品? 访问 产品对比指南
一般描述
Our Mobius® High Cell Density Cryopreservation (HCDC) Assembly (-196C) is a single-use assembly specially designed to facilitate the freeze and thaw of cryopreserved cells in liquid nitrogen vapor phase (? -196°C). Available in two assembly bag sizes of 100 mL and 250 mL, our Mobius® HCDC Assembly (-196C) enables seed train inoculation with cells at a higher cell density and larger volume compared to the traditional seed train process using vials, which significantly accelerates the cell expansion process. Our Mobius® single-use assembly also provides a closed processing environment preventing contamination while improving process reproducibility.
特异性
Application
应用
包装
组分
Pinch clamp: Nylon
其他说明
法律信息
Not finding the right product?
Try our 产品选型工具.
法规信息
商品
This page describes the design attributes of the Cellicon® filter assembly for cell retention and how they simplify scale-up of intensified upstream processes.
Understand how considerations such as DMSO concentrations and freezing techniques are key in the successful implementation of high cell density cryopreservation (HCDC).
High cell density cryopreservation (HCDC) is a closed processing alternative to the traditional seed train expansion process. Learn more about the benefits of HCDC.
How the Cellicon® filter and controller enables seamless adoption of a perfused N-1 seed train step into the cell expansion process.
相关内容
生物制药开发商需要高效、高产的上游工艺来提供优质的单克隆抗体(mAb)和其他类型重组蛋白。工艺强化可确保生产策略适应未来发展需求、降低成本并提升设施灵活性。
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
生物制药开发商需要高效、高产的上游工艺来提供优质的单克隆抗体(mAb)和其他类型重组蛋白。工艺强化可确保生产策略适应未来发展需求、降低成本并提升设施灵活性。
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门